JPWO2020112796A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020112796A5 JPWO2020112796A5 JP2021531294A JP2021531294A JPWO2020112796A5 JP WO2020112796 A5 JPWO2020112796 A5 JP WO2020112796A5 JP 2021531294 A JP2021531294 A JP 2021531294A JP 2021531294 A JP2021531294 A JP 2021531294A JP WO2020112796 A5 JPWO2020112796 A5 JP WO2020112796A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- cells
- dose
- amino acid
- acid sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000004027 cells Anatomy 0.000 claims description 221
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 136
- BGFTWECWAICPDG-UHFFFAOYSA-N 2-[bis(4-chlorophenyl)methyl]-4-N-[3-[bis(4-chlorophenyl)methyl]-4-(dimethylamino)phenyl]-1-N,1-N-dimethylbenzene-1,4-diamine Chemical compound C1=C(C(C=2C=CC(Cl)=CC=2)C=2C=CC(Cl)=CC=2)C(N(C)C)=CC=C1NC(C=1)=CC=C(N(C)C)C=1C(C=1C=CC(Cl)=CC=1)C1=CC=C(Cl)C=C1 BGFTWECWAICPDG-UHFFFAOYSA-N 0.000 claims description 44
- 108010008014 B-Cell Maturation Antigen Proteins 0.000 claims description 44
- 102000006942 B-Cell Maturation Antigen Human genes 0.000 claims description 44
- 102100008191 CD8A Human genes 0.000 claims description 30
- 101700054655 CD8A Proteins 0.000 claims description 30
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims description 26
- 230000004068 intracellular signaling Effects 0.000 claims description 26
- 239000000203 mixture Substances 0.000 claims description 19
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 18
- 201000009251 multiple myeloma Diseases 0.000 claims description 18
- 108090001123 antibodies Proteins 0.000 claims description 12
- 102000004965 antibodies Human genes 0.000 claims description 12
- 230000011664 signaling Effects 0.000 claims description 12
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims description 11
- 102100019283 CD52 Human genes 0.000 claims description 10
- 108010065524 CD52 Antigen Proteins 0.000 claims description 10
- 238000009472 formulation Methods 0.000 claims description 10
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims description 8
- 229960004397 Cyclophosphamide Drugs 0.000 claims description 8
- 102100000165 MS4A1 Human genes 0.000 claims description 8
- 101710010909 MS4A1 Proteins 0.000 claims description 8
- 230000027455 binding Effects 0.000 claims description 8
- 229960000390 fludarabine Drugs 0.000 claims description 8
- GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 claims description 8
- 108010001645 Rituximab Proteins 0.000 claims description 6
- 108020001756 ligand binding domains Proteins 0.000 claims description 6
- 229960004641 rituximab Drugs 0.000 claims description 6
- 108010070144 Single-Chain Antibodies Proteins 0.000 claims description 4
- 102000005632 Single-Chain Antibodies Human genes 0.000 claims description 4
- 210000001744 T-Lymphocytes Anatomy 0.000 claims description 4
- 230000002950 deficient Effects 0.000 claims description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 4
- 230000000306 recurrent Effects 0.000 claims description 3
- 239000004480 active ingredient Substances 0.000 claims description 2
- 230000000735 allogeneic Effects 0.000 claims description 2
- 230000026683 transduction Effects 0.000 claims description 2
- 238000010361 transduction Methods 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 38
- 239000003814 drug Substances 0.000 claims 3
- 210000004698 Lymphocytes Anatomy 0.000 claims 1
- 239000007788 liquid Substances 0.000 description 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862774209P | 2018-12-01 | 2018-12-01 | |
| US62/774,209 | 2018-12-01 | ||
| US201962816187P | 2019-03-10 | 2019-03-10 | |
| US62/816,187 | 2019-03-10 | ||
| US201962931487P | 2019-11-06 | 2019-11-06 | |
| US62/931,487 | 2019-11-06 | ||
| PCT/US2019/063282 WO2020112796A1 (en) | 2018-12-01 | 2019-11-26 | Chimeric antigen receptors targeting b-cell maturation antigen and methods of use thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022513691A JP2022513691A (ja) | 2022-02-09 |
| JPWO2020112796A5 true JPWO2020112796A5 (zh) | 2022-12-05 |
Family
ID=69063865
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021531294A Pending JP2022513691A (ja) | 2018-12-01 | 2019-11-26 | Ｂ細胞成熟抗原を標的とするキメラ抗原受容体およびその使用方法 |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20200261503A1 (zh) |
| EP (1) | EP3886989A1 (zh) |
| JP (1) | JP2022513691A (zh) |
| KR (1) | KR20210099574A (zh) |
| CN (1) | CN113498353A (zh) |
| AU (1) | AU2019386063A1 (zh) |
| BR (1) | BR112021010279A2 (zh) |
| CA (1) | CA3116720A1 (zh) |
| CO (1) | CO2021005004A2 (zh) |
| IL (1) | IL283144A (zh) |
| MX (1) | MX2021006395A (zh) |
| PE (1) | PE20211915A1 (zh) |
| PH (1) | PH12021550909A1 (zh) |
| SG (1) | SG11202105353PA (zh) |
| TW (1) | TW202039544A (zh) |
| WO (1) | WO2020112796A1 (zh) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL297223A (en) | 2015-04-13 | 2022-12-01 | Pfizer | Chimeric antigen receptors antigen-directed maturation of b cells |
| AU2022257093A1 (en) | 2021-04-16 | 2023-11-02 | Celgene Corporation | T cell therapy in patients who have had prior stem cell transplant |
| CA3228311A1 (en) * | 2021-08-12 | 2023-02-16 | Ke HE | Bispecific recombinant protein and use thereof |
| JP2024540320A (ja) | 2021-11-03 | 2024-10-31 | セルジーン コーポレーション | 骨髄腫を処置する際に使用するための、ｂ細胞成熟抗原に特異的なキメラ抗原受容体 |
| KR20240137075A (ko) | 2022-01-28 | 2024-09-19 | 주노 쎄러퓨티크스 인코퍼레이티드 | 세포 조성물의 제조 방법 |
| AU2023219348A1 (en) * | 2022-02-09 | 2024-08-22 | Bar Ilan University | Anti-bcma car to target immune-related disorders, compositions and method thereof |
| WO2023220641A2 (en) | 2022-05-11 | 2023-11-16 | Juno Therapeutics, Inc. | Methods and uses related to t cell therapy and production of same |
| WO2023220655A1 (en) | 2022-05-11 | 2023-11-16 | Celgene Corporation | Methods to overcome drug resistance by re-sensitizing cancer cells to treatment with a prior therapy via treatment with a t cell therapy |
| WO2023230548A1 (en) | 2022-05-25 | 2023-11-30 | Celgene Corporation | Method for predicting response to a t cell therapy |
| WO2023230581A1 (en) | 2022-05-25 | 2023-11-30 | Celgene Corporation | Methods of manufacturing t cell therapies |
| WO2024097905A1 (en) | 2022-11-02 | 2024-05-10 | Celgene Corporation | Methods of treatment with t cell therapy and immunomodulatory agent maintenance therapy |
| WO2024168192A1 (en) | 2023-02-10 | 2024-08-15 | Celgene Corporation | Assessment of bcma in biological samples |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201206559D0 (en) | 2012-04-13 | 2012-05-30 | Ucl Business Plc | Polypeptide |
| AU2015248956B2 (en) * | 2014-04-14 | 2020-06-25 | Cellectis | BCMA (CD269) specific chimeric antigen receptors for cancer immunotherapy |
| WO2016120217A1 (en) | 2015-01-26 | 2016-08-04 | Cellectis | Anti-hsp70 specific chimeric antigen receptors (cars) for cancer immunotherapy |
| MY196625A (en) * | 2015-04-13 | 2023-04-23 | Pfizer | Therapeutic Antibodies and Their Uses |
| IL297223A (en) * | 2015-04-13 | 2022-12-01 | Pfizer | Chimeric antigen receptors antigen-directed maturation of b cells |
| CA2954014A1 (en) * | 2016-01-21 | 2017-07-21 | Oi Kwan WONG | Chimeric antigen receptors targeting epidermal growth factor receptor variant iii |
-
2019
- 2019-11-26 JP JP2021531294A patent/JP2022513691A/ja active Pending
- 2019-11-26 TW TW108142941A patent/TW202039544A/zh unknown
- 2019-11-26 AU AU2019386063A patent/AU2019386063A1/en active Pending
- 2019-11-26 MX MX2021006395A patent/MX2021006395A/es unknown
- 2019-11-26 KR KR1020217017239A patent/KR20210099574A/ko unknown
- 2019-11-26 CN CN201980079534.9A patent/CN113498353A/zh active Pending
- 2019-11-26 BR BR112021010279-5A patent/BR112021010279A2/pt unknown
- 2019-11-26 SG SG11202105353PA patent/SG11202105353PA/en unknown
- 2019-11-26 EP EP19829720.2A patent/EP3886989A1/en active Pending
- 2019-11-26 US US16/695,894 patent/US20200261503A1/en active Pending
- 2019-11-26 CA CA3116720A patent/CA3116720A1/en active Pending
- 2019-11-26 WO PCT/US2019/063282 patent/WO2020112796A1/en active Application Filing
- 2019-11-26 PE PE2021000780A patent/PE20211915A1/es unknown
-
2021
- 2021-04-19 CO CONC2021/0005004A patent/CO2021005004A2/es unknown
- 2021-04-22 PH PH12021550909A patent/PH12021550909A1/en unknown
- 2021-05-12 IL IL283144A patent/IL283144A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20240041995A1 (en) | Anti-icos agonist antibodies and uses thereof | |
| US20220098302A1 (en) | Combination of dr5 agonist and anti-pd-1 antagonist and methods of use | |
| US20230111786A1 (en) | Compositions comprising a combination of an anti-lag-3 antibody, a pd-1 pathway inhibitor, and an immunotherapeutic agent | |
| KR20210002499A (ko) | 항-cd38 항체의 피하 투여 | |
| TW201625270A (zh) | 用於治療贅瘤形成的治療組合及方法 | |
| US11685787B2 (en) | Treatment of cancer with anti-GITR agonist antibodies | |
| US20210395392A1 (en) | Anti-mertk antibodies for treating cancer | |
| WO2020261093A1 (en) | Dosing regimen and combination therapies for multispecific antibodies targeting b-cell maturation antigen | |
| JPWO2020112796A5 (zh) | ||
| JP2024099018A (ja) | 免疫細胞関与効果を調節するための手段および方法。 | |
| RU2021115040A (ru) | Химерные антигенные рецепторы, нацеленные на антиген созревания в-клеток, и способы их применения | |
| EA041306B1 (ru) | Агонистические антитела против icos и их применение |